Can Adropin peptides be a biomarker for traumatic brain injury? A prospective study

INTRODUCTION: Traumatic brain injury continues to be a severe health problem worldwide due to its significant mortality and morbidity. Computed Tomography and Glasgow coma scale are the main diagnostic methods used to determine the severity of traumatic brain injury today. However, both methods have their limitations. Therefore, biomarkers that can reliably reflect the extent of post-traumatic brain injury and microscopic pathological events have been sought for a long time.Our study aims to investigate whether serum adropin levels can be a biomarker used in adult head trauma
METHODS: The study was designed as a prospective study of adult patients admitted to the emergency department with isolated head trauma. A demographic information form was filled for each individual participating in the study. All patient evaluations were made by emergency medicine specialists. The study population consisted of patients who required computerized brain tomography at the time of admission. The blood samples were obtained within the first hour of admission to the emergency room.
RESULTS: : Adropin levels in the patient group were statistically significantly higher than in the control group (p=<0.000). Besides, no statistically significant difference was found in serum Adropin levels between the patient group who had bleeding and fractures determined in the brain tomography and those with no pathological findings (p=0.723)
DISCUSSION AND CONCLUSION: We think that adropin may have protective or curative effects on the human brain.